repaglinide vs control (add on MET) | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs glibenclamide | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs glipizide | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs metformin | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs on top pioglitazone | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs on top rosiglitazone | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs on top troglitazone | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs placebo | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
repaglinide vs placebo (on top bedtime NPH-insulin) | No demonstrated result | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |